查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553581

照護現場傳染病檢查市場規模、佔有率和趨勢分析報告：2024-2030 年按技術、疾病、最終用途、地區和細分市場進行的預測

Point Of Care Infectious Disease Testing Market Size, Share & Trends Analysis Report By Technology, By Disease (HIV POC, Clostridium Difficile POC), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

照護現場傳染病檢查市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球照護現場傳染病檢查市場規模預計將達到157.6億美元，複合年成長率為4.3%。

以患者為中心的服務的新興趨勢，加上複雜感染疾病病率的上升，預計將急劇增加對可攜式和準確檢測設備的需求，推動市場成長。這些設備能夠快速檢測感染疾病的潛力正在推動估計市場的發展。

此外，這些設備帶來的患者照護創新正在推動對分散式檢查環境不斷成長的需求。預計到 2025 年，新產品研發和市場開拓的投資增加將刺激照護現場感染疾病診斷市場的發展。

例如，歐盟計劃研究小組開發的一種新的「光碟實驗室」技術可以幫助診斷包括瘧疾在內的各種感染疾病。即時治療的引入可以實現更快的診斷。這可以實現精確的藥物劑量並影響吸收。

照護現場傳染病檢查市場報告亮點

  • COVID-19 細分市場佔據主導地位，到 2023 年將佔據 67% 的佔有率。這一高比率是由於感染疾病患者數量不斷增加以及對快速且易於使用的診斷測試解決方案的需求。
  • 預計側流免疫測量在預測期內的複合年成長率將達到 5.7%，是最快的。這一成長是由呼吸系統疾病等感染疾病的日益流行以及照護現場診斷設備的技術進步所推動的。
  • 預計家庭產業在預測期內將以 5.5% 的複合年成長率成長最快。這是由於老年人擴大採用 POC 測試，並且越來越重視個人化、預防性居家照護設施。
  • 由於在政府的充分支持下，感染疾病發病率和盛行率不斷上升，預計亞太地區將在預測期內出現最快的成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章照護現場傳染病檢查市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 照護現場傳染病檢查市場分析工具
    • 波特的分析
    • PESTEL分析

第4章照護現場傳染病檢查市場：技術估算與趨勢分析

  • 細分儀表板
  • 照護現場傳染病檢查市場：2023 年和 2030 年技術變化分析
  • 側流免疫檢測
  • 凝集試驗
  • 流通測試/免疫富集測定
  • 分子診斷
  • 其他

第5章照護現場傳染病檢查市場：依疾病分類的估計與趨勢分析

  • 細分儀表板
  • 照護現場傳染病檢查市場：2023 年及 2030 年依疾病分類的變異分析
  • HIV POC
  • 困難梭狀芽孢桿菌POC
  • HBV POC
  • 肺炎或鏈球菌相關感染疾病
  • 呼吸道融合細胞病毒(RSV) POC
  • HPV POC
  • 流感/流感 POC
  • HCV POC
  • MRSA POC
  • 結核病和抗藥性結核病的 POC
  • HSV POC
  • COVID-19
  • 其他感染疾病

第6章照護現場傳染病檢查市場：依最終用途分類的估計與趨勢分析

  • 細分儀表板
  • 照護現場傳染病檢查市場：2023 年和 2030 年最終用途的變化分析
  • 診所
  • 醫院
  • 房子
  • 生活協助醫療設施
  • 實驗室

第7章照護現場傳染病檢查市場：區域估計與趨勢分析

  • 2023 年和 2030 年按地區照護現場傳染病檢查市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Abbott
    • Thermo Fisher Scientific Inc
    • F. Hoffmann-La Roche Ltd
    • Siemens Healthineers
    • Becton, Dickinson &Company
    • Chembio Diagnostics Inc.
    • Trinity Biotech
    • Cardinal Health
    • Quest Diagnostics Incorporated
    • Bio-Rad Laboratories Inc.
    • bioMerieux SA
    • Sight Diagnostics Ltd.
    • Gene POC
    • Trivitron Healthcare
    • OJ-Bio Ltd.
    • Ortho-Clinical Diagnostics.
簡介目錄
Product Code: GVR-1-68038-569-4

Point Of Care Infectious Disease Testing Market Growth & Trends:

The global point of care infectious disease testing market size is expected to reach USD 15.76 billion by 2030, registering a CAGR of 4.3%, according to a new report by Grand View Research, Inc. The emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth. The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.

Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings. Rise in the investments for R&D and development of new products is expected to spur progress in point-of-care infectious disease diagnostics market through to 2025.

For instance, development of a new 'lab-on-a-disc' technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment. This allows precise drugs administration thus influencing adoption rate.

Point Of Care Infectious Disease Testing Market Report Highlights:

  • COVID-19 segment dominated the market and accounted for a share of 67% in 2023. This high percentage can be attributed to the rising number of infectious cases and need for fast and accessible diagnostics testing solutions.
  • Lateral flow immunoassay is expected to register the fastest CAGR of 5.7% during the forecast period. The growth can be attributed to increasing prevalence of infectious diseases such as respiratory disease and technological advancements in point of care diagnostics device.
  • The home segment is projected to grow at the fastest CAGR of 5.5% over the forecast period, owing to increasing adoption of point of care testing among geriatric population and increasing emphasis on personalized and preventive home care facilities.
  • Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Point of Care Infectious Disease Testing Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Point of Care Infectious Disease Testing Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Point of Care Infectious Disease Testing Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Point of Care Infectious Disease Testing Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Lateral Flow Immunoassay
    • 4.3.1. Lateral Flow Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Agglutination Test
    • 4.4.1. Agglutination Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Flow-through test/Immunoconcentration Assay
    • 4.5.1. Flow-through test/Immunoconcentration Assay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.6. Molecular Diagnostics
    • 4.6.1. Molecular Diagnostics Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.7. Others
    • 4.7.1. Others Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Point of Care Infectious Disease Testing Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Point of Care Infectious Disease Testing Market: Disease Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.3. HIV POC
    • 5.3.1. HIV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Clostridium Difficile POC
    • 5.4.1. Clostridium Difficile POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. HBV POC
    • 5.5.1. HBV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Pneumonia or Streptococcus Associated Infections
    • 5.6.1. Pneumonia or Streptococcus Associated Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Respiratory Syncytial Virus (RSV) POC
    • 5.7.1. Respiratory Syncytial Virus (RSV) POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8. HPV POC
    • 5.8.1. HPV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.9. Influenza/Flu POC
    • 5.9.1. Influenza/Flu POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.10. HCV POC
    • 5.10.1. HCV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.11. MRSA POC
    • 5.11.1. MRSA POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.12. TB and Drug-resistant TB POC
    • 5.12.1. TB and Drug-resistant TB POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.13. HSV POC
    • 5.13.1. HSV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.14. COVID-19
    • 5.14.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.15. Other Infectious Diseases
    • 5.15.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Point of Care Infectious Disease Testing Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Point of Care Infectious Disease Testing Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Clinics
    • 6.3.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Home
    • 6.5.1. Home Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Assisted Living Healthcare Facilities
    • 6.6.1. Assisted Living Healthcare Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.7. Laboratory
    • 6.7.1. Laboratory Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Point of Care Infectious Disease Testing Market: Regional Estimates & Trend Analysis

  • 7.1. Point of Care Infectious Disease Testing Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. North America
    • 7.2.1. North America Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Point of Care Infectious Disease Diagnostic Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Abbott
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Thermo Fisher Scientific Inc
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. F. Hoffmann-La Roche Ltd
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Siemens Healthineers
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Becton, Dickinson & Company
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Chembio Diagnostics Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Trinity Biotech
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Cardinal Health
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Quest Diagnostics Incorporated
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Bio-Rad Laboratories Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. bioMerieux SA
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. Sight Diagnostics Ltd.
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives
    • 8.4.13. Gene POC
      • 8.4.13.1. Participant's Overview
      • 8.4.13.2. Financial Performance
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Recent Developments/ Strategic Initiatives
    • 8.4.14. Trivitron Healthcare
      • 8.4.14.1. Participant's Overview
      • 8.4.14.2. Financial Performance
      • 8.4.14.3. Product Benchmarking
      • 8.4.14.4. Recent Developments/ Strategic Initiatives
    • 8.4.15. OJ-Bio Ltd.
      • 8.4.15.1. Participant's Overview
      • 8.4.15.2. Financial Performance
      • 8.4.15.3. Product Benchmarking
      • 8.4.15.4. Recent Developments/ Strategic Initiatives
    • 8.4.16. Ortho-Clinical Diagnostics.
      • 8.4.16.1. Participant's Overview
      • 8.4.16.2. Financial Performance
      • 8.4.16.3. Product Benchmarking
      • 8.4.16.4. Recent Developments/ Strategic Initiatives